Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2015 Sep 20;33(27):2949-62.
doi: 10.1200/JCO.2015.62.8289. Epub 2015 Aug 24.

Collaborative Efforts Driving Progress in Pediatric Acute Myeloid Leukemia

Affiliations
Free PMC article
Review

Collaborative Efforts Driving Progress in Pediatric Acute Myeloid Leukemia

C Michel Zwaan et al. J Clin Oncol. .
Free PMC article

Abstract

Diagnosis, treatment, response monitoring, and outcome of pediatric acute myeloid leukemia (AML) have made enormous progress during the past decades. Because AML is a rare type of childhood cancer, with an incidence of approximately seven occurrences per 1 million children annually, national and international collaborative efforts have evolved. This overview describes these efforts and includes a summary of the history and contributions of each of the main collaborative pediatric AML groups worldwide. The focus is on translational and clinical research, which includes past, current, and future clinical trials. Separate sections concern acute promyelocytic leukemia, myeloid leukemia of Down syndrome, and relapsed AML. A plethora of novel antileukemic agents that have emerged, including new classes of drugs, are summarized as well. Finally, an important aspect of the treatment of pediatric AML--supportive care--and late effects are discussed. The future is bright, with a wide range of emerging innovative therapies and with more and more international collaboration that ultimately aim to cure all children with AML, with fewer adverse effects and without late effects.

Conflict of interest statement

Authors' disclosures of potential conflicts of interest are found in the article online at www.jco.org. Author contributions are found at the end of this article.

Figures

Fig 1.
Fig 1.
(A) Distribution of genetic abnormalities in pediatric acute myeloid leukemia (AML). Collaborating type I and type II mutations in pediatric AML. The circos plot depicts the frequency of the type II mutations and co-occurrence of type I mutations in patients with de novo pediatric AML. The length of the arch corresponds with the frequency of the type II mutation, and the width of the ribbon corresponds with the percentage of patients who have a specific type I mutation or combination of type I mutations. (B) Overview of co-occurring mutations in pediatric cytogenetically normal (CN) AML (N = 53). Each column represents a single occurrence. A colored field means that the occurrence is positive for a mutation or translocation in the corresponding gene(s). A white field indicates that the occurrence tested negative for a mutation or translocation in the corresponding gene(s). A gray field indicates an occurrence that could not be tested for mutations in the corresponding gene. dm, double mutations; ITD, internal tandem duplication; PTD, partial tandem duplication; sm, small mutations.

Similar articles

See all similar articles

Cited by 49 articles

See all "Cited by" articles

Publication types

MeSH terms

Feedback